IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy

Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC).

(2017) Asim Amin et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclophosphamide Induces a Type I Interferon-Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy

(2013) F. Moschella et al.   CLINICAL CANCER RESEARCH

Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors

(2013) Franziska Stehle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

(2013) S. Viaud et al.   SCIENCE

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

(2013) Jens Bedke et al.   WORLD JOURNAL OF UROLOGY

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

(2012) Philippe Fournier et al.   BIODRUGS

76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma

(2012) J. Bedke et al.   EUROPEAN UROLOGY SUPPLEMENTS

Second-line systemic therapy for the treatment of metastatic renal cell cancer

(2012) Stephan Kruck et al.   Expert Review of Anticancer Therapy

Cyclophosphamide Promotes Chronic Inflammation–Dependent Immunosuppression and Prevents Antitumor Response in Melanoma

(2012) Alexandra Sevko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model

(2012) Anamika Bose et al.   MELANOMA RESEARCH

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial watch

(2012) Erika Vacchelli et al.   OncoImmunology

Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901

(2012) Steffen Walter et al.   OncoImmunology

Toll-Like Receptor 4 Activation in Cancer Progression and Therapy

(2011) Alja Oblak et al.   Clinical & Developmental Immunology

Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma

(2011) Stephen J. Schuster et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients

(2010) S. Viaud et al.   CANCER RESEARCH

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2010) R. J. Amato et al.   CLINICAL CANCER RESEARCH

EAU Guidelines on Renal Cell Carcinoma: The 2010 Update

(2010) Börje Ljungberg et al.   EUROPEAN UROLOGY

Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?

(2010) Sabine Brookman-May et al.   Expert Review of Anticancer Therapy

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations

(2010) F. F. Gonzalez-Galarza et al.   NUCLEIC ACIDS RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY

Immunotherapeutic strategies in kidney cancer—when TKIs are not enough

(2009) Swethajit Biswas et al.   Nature Reviews Clinical Oncology

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer

(2009) Susan Feyerabend et al.   PROSTATE

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma

(2008) S. Kusmartsev et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Vitespen: a vaccine for renal cancer?

(2008) James C Yang   LANCET

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

(2008) Christopher Wood et al.   LANCET